Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have reported new dopamine D1 and/or D5 receptor partial agonists. As such, they are reported to be useful for the treatment schizophrenia, attention deficit hyperactivity disorder (ADHD), Tourette disease, sleep disorder, pain, autism spectrum disorder, Parkinson’s and Alzheimer’s disease, among others.
Beijing Sciwind Biotechnology Co. Ltd. and Sciwind Biosciences Co. Ltd. have disclosed new corticotropin-releasing factor CRF2 receptor (CRFH2) agonists potentially useful for the treatment of heart failure, hypertension, obesity, sarcopenia, diabetes and chronic kidney diseases.
Gan & Lee Pharmaceuticals Co. Ltd. has divulged new molecular glue degraders comprising cereblon (CRBN)-binding agents and casein kinase 1 isoform α (CK1α, CSNK1A1) degradation moieties potentially useful for the treatment of cancer.
Teikyo University has synthesized new neutrophil elastase (ELANE; leukocyte elastase) inhibitors potentially useful for the treatment of acute lung injury.
Eioncell Co. Ltd. and Hallym University have reported new antibody-drug conjugates (ADCs) comprising an antibody targeting kita-kyushu lung cancer antigen 1 (KK-LC-1; CT83) linked to a cytotoxic drug potentially useful for the treatment of cancer.
Kyowa Kirin Co. Ltd. has identified new solute carrier family 15 member 4 (SLC15A4) inhibitors potentially useful for the treatment of autoimmune disease and lupus nephritis.
Gilead Sciences Inc. has described GTPase KRAS inhibitors, particularly wild-type KRAS, KRAS (G12C mutant), KRAS (G12D mutant) and/or KRAS (G12V mutant) inhibitors, found to be potentially useful for the treatment of cancer.
RSS